New drug combo aims to shrink lung tumors before surgery

NCT ID NCT05247684

Ongoing Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This phase II trial is testing a new drug called AK112, alone or with chemotherapy, in people with resectable non-small cell lung cancer. The goal is to see if giving the treatment before and after surgery can help shrink tumors and prevent the cancer from coming back. The study involves 90 participants and focuses on safety and how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK112 (a bispecific antibody targeting PD-1 and VEGF), carboplatin, cisplatin, paclitaxel
What this could lead to: If successful, this could offer a new treatment option to shrink lung tumors before surgery and reduce the chance of cancer returning afterward.
What could go wrong: This is an early phase II trial with only 90 participants, so results may not apply to everyone. Side effects from the drug combination could be significant, and the treatment may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESECTABLE NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.